127
Participants
Start Date
January 13, 2020
Primary Completion Date
November 4, 2024
Study Completion Date
November 4, 2024
BG505 SOSIP.664 gp140
Administered by IM injection
Placebo
Administered by IM injection
3M-052-AF
Administered by IM injection
CpG 1018
Administered by IM injection
GLA-LSQ
Administered by IM injection
Alum (Aluminum Hydroxide Suspension)
Administered by IM injection
Trimer 4571
Administered by IM injection
Columbia P&S CRS, New York
New York Blood Center CRS (Site 31801), New York
University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester
University of Pittsburgh CRS, Pittsburgh
Penn Prevention CRS, Philadelphia
The Hope Clinic of the Emory Vaccine Center CRS, Decatur
Alabama CRS, Birmingham
The Ponce de Leon Center CRS, Atlanta
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston
Seattle Vaccine and Prevention CRS, Seattle
Collaborators (1)
HIV Vaccine Trials Network
NETWORK
International AIDS Vaccine Initiative
NETWORK
Access to Advanced Health Institute (AAHI)
OTHER
Dynavax Technologies Corporation
INDUSTRY
Fred Hutchinson Cancer Center
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH